Scarica l'app Stockscreener
55.83
0.07%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$55.79
Aprire:
$55.43
Volume 24 ore:
10.12M
Relative Volume:
0.99
Capitalizzazione di mercato:
$113.30B
Reddito:
$48.30B
Utile/perdita netta:
$-8.95B
Rapporto P/E:
-12.63
EPS:
-4.42
Flusso di cassa netto:
$13.94B
1 W Prestazione:
+3.58%
1M Prestazione:
-2.12%
6M Prestazione:
+15.26%
1 anno Prestazione:
+9.66%
Intervallo 1D:
$54.85
$56.05
Intervallo di 1 settimana:
$53.54
$56.05
Portata 52W:
$39.35
$61.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
55.83 | 113.30B | 48.30B | -8.95B | 13.94B | -4.42 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week - MSN
Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week (BMY:NYSE) - Seeking Alpha
Bristol Myers Squibb CEO Christopher Boerner buys $110,096 in stock - Investing.com India
Bristol Myers Squibb CEO Christopher Boerner buys $110,096 in stock By Investing.com - Investing.com UK
Bristol Myers Squibb CEO Acquires 2,000 Shares - TradingView
Bristol-Myers GC Sandra Leung To Retire After 33 Years - Law360
BMY: 3 Precision Medicine Stocks That Could Transform Healthcare - StockNews.com
CAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight - GlobeNewswire Inc.
Cell Therapy Market Is Booming So Rapidly with Forecast by 2032 | Bristol Myers Squibb Company, Amgen, Johnson - EIN News
Paradigm Asset Management Co. LLC Has $2.23 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Clinical Trial Manager Job – at Bristol Myers Squibb, Apply Now! - BioTecNika
Braun Stacey Associates Inc. Makes New $19.71 Million Investment in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
High Potency Drug Market Top PlayersNovartis AG, Bristol-Myers Squibb Co, Sanofi, Takeda Pharmaceutical Co Ltd. - openPR
Truist Financial Corp Purchases 60,365 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb veteran general counsel to retire - | Governance Intelligence
GAM Holding AG Sells 39,363 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Names New GC as Legal Chief Retires - Bloomberg Law
Compugen Updates Filing Structure with Bristol Myers Squibb - MSN
BioArctic-Bristol Myers Squibb Alzheimer's Deal Clears US Regulatory Hurdle -February 20, 2025 at 01:43 am EST - Marketscreener.com
Bristol Myers Squibb exec Samit Hirawat acquires $99,999 in stock By Investing.com - Investing.com Nigeria
FTC approves Bioarctic's license agreement with Bristol Myers Squibb -February 20, 2025 at 01:18 am EST - Marketscreener.com
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing - Yahoo Finance
BMYBristol-Myers Squibb Co Latest Stock News & Market Updates - StockTitan
Bristol Myers Squibb exec Samit Hirawat acquires $99,999 in stock - Investing.com India
Bristol Myers Squibb EVP Purchases Company Shares - TradingView
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer - Benzinga
Bristol Myers Squibb GC to Retire After 33 years With Drugmaker - Law.com
Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLC - FiercePharma
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer - Business Wire
Convergence Investment Partners LLC Buys 6,888 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Rancho BioSciences Announces Bristol Myers Squibb Renews Membership for Phase 2 of the Single-Cell Data Science Consortium - BioSpace
Bristol Myers: positive Phase 3 data in NSCLC -February 19, 2025 at 07:48 am EST - Marketscreener.com
Bristol Myers announces new five-year results from POETYK PSO trial - Yahoo Finance
Valley Wealth Managers Inc. Sells 7,824 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
D.A. Davidson & CO. Purchases 7,343 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Allworth Financial LP Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Rep. Julie Johnson Purchases Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Areas of interest - Bristol Myers Squibb
Cancer Therapy Market Is Booming Worldwide 2025-2032 | Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc. - openPR
Bank Pictet & Cie Europe AG Purchases Shares of 231,500 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Position Increased by Roman Butler Fullerton & Co. - MarketBeat
Covenant Asset Management LLC Acquires New Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
New York State Teachers Retirement System Has $104.57 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
AustralianSuper Pty Ltd Sells 398,552 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1 - 2 Minute Medicine
KLCM Advisors Inc. Decreases Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
AlphaCentric Advisors LLC Makes New $1.11 Million Investment in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol-Myers Squibb (BMY) Is Among the Best Drug Stocks to Buy Now - Insider Monkey
Bristol Myers: positive five-year results for Sotyktu -February 17, 2025 at 02:04 am EST - Marketscreener.com
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.61%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):